GlassScriptPhysician profile
Tong Yang
NPI 1811296718
$7,467.97
in general payments reported to CMS, 2019-2025
9 companies · $192 in 2025
The $192 reported for 2025 was more than what 79% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,412 · 2020: $110 · 2021: $14.10 · 2022: $107 · 2023: $97.89 · 2024: $534 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,471.98 | 2019-2025 | Onglyza |
| Tempus Ai, INC | $288.71 | 2024 | |
| Abbott Laboratories | $251.42 | 2019-2025 | Alinity M |
| Ipsen Biopharmaceuticals, INC | $142.44 | 2024 | Tazverik |
| Genentech USA, INC. | $110.46 | 2020 | |
| Merck Sharp & Dohme LLC | $70.11 | 2019-2022 | |
| Genzyme Corporation | $59.90 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $52.08 | 2022 | |
| Werfen USA LLC | $20.87 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tong Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.